Aquisition Boosts Medigene’s Immuno-oncology Portfolio

Frankfurt based Medigene last week acquired fellow Germans Trianta for the sum of €9.9 ($13.5). Trianta Immnotherapies, a Munich based  start-up, develops novel cancer vaccines and development platforms, sepcialising in personalised T cell immunotherapy. The move will see Medigene gaining 15 of the country’s top cancer vaccine researchers from the German Research Center for Environmental Health (Helmholtz Zentrum Munchen). Trianta …